Nordion sells Belgian operation

Published: 22-Feb-2011
Finance Cleaning Analysis

Best Medical to buy MDS Nordion, terms not revealed

Nordion, a Canadian provider of medical isotopes and sterilisation technologies for the prevention, diagnosis and treatment of cancer, has sold its loss-making Belgian operation, MDS Nordion, to Best Medical Belgium.

Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.

Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.

The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.

Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.

The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.

Nordion expects the transaction to be completed in the next few months.

See more

You may also like

Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Read more
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model

Trending Articles

  1. BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
  2. Romaco Holding GmbH Romaco is a leading international supplier of machinery and integrated system solutions for the development, production and packaging of pharmaceuticals, nutraceuticals, food, cosmetic and chemical products. All from a single source.
  3. Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    AstraZeneca resumes £300m UK investment as drug pricing and tariff landscape shifts The Cambridge and Macclesfield programmes, paused amid NHS reimbursement disputes, are back on track following the US-UK pharmaceutical deal and a revised NHS rebate rate
  5. AES Cleanroom Technology appoints John Groth as Chief Revenue Officer AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer as demand grows for flexible, high-performance manufacturing environments across pharma and biotech

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing

BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany

The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

AstraZeneca resumes £300m UK investment as drug pricing and tariff landscape shifts

The Cambridge and Macclesfield programmes, paused amid NHS reimbursement disputes, are back on track following the US-UK pharmaceutical deal and a revised NHS rebate rate
Finance

BASF reports Q1 earnings as currency headwinds and Middle East conflict weigh on revenue

The German chemicals giant posted solid volume growth across most segments in the first quarter of 2026, but adverse currency effects eroded sales and pushed EBITDA before special items down
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Subscribe now